NCT07414836

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	BG-C0979	Administered by intravenous infusion.
DRUG	Tislelizumab	Administered by intravenous infusion.

Timeline

• Start date: 2026-04-30
• Primary completion: 2029-04-30
• Completion: 2029-04-30
• First posted: 2026-02-17
• Last updated: 2026-02-17

Regulatory

• FDA-regulated drug study